Skip to main content
European Commission logo print header

A novel approach to non-invasive and personalized skin cancer diagnosis

Descrizione del progetto

Rivoluzionare la diagnostica del tumore cutaneo

La società francese DAMAE Medical sta sviluppando una nuova diagnostica dermatologica basata su una dirompente tecnologia di tomografia ottica a radiazione coerente confocale linea-campo in un dispositivo di imaging portatile. Il dispositivo acquisisce immagini in situ degli strati cutanei con risoluzione cellulare e fornisce una diagnosi accurata, riducendo così al minimo le biopsie di lesioni benigne e migliorando il rilevamento dei tumori cutanei di tipo melanoma e non-melanoma. Allo stesso tempo, DAMAE sta sviluppando un software per coadiuvare i dermatologi nell’interpretazione delle immagini e per la telepatologia e i servizi ai pazienti. L’azienda ha completato la fase di fattibilità, risultante in un prototipo della tecnologia e in un atlante consolidato di immagini cliniche del tumore cutaneo. L’obiettivo principale dell’attuale fase 2 del progetto OCTAV, finanziato dall’UE, è ottenere la valutazione del mercato, la convalida clinica e l’approvazione normativa.

Obiettivo

French SME-company DAMAE Medical is facing skin cancer worldwide issue by developing the OCTAV Project, a new approach to
dermatological diagnostic based on a disruptive Line-field Confocal Optical Coherence Tomography (LC-OCT) technology, in a novel
hand-held imaging device.
OCTAV is designed to capture in situ images of the skin layers with a cellular resolution. It is used in conjunction with dermoscopy to
provide more accurate diagnosis, leading to fewer biopsies of benign lesions and earlier detection of melanoma (clinical use 1) and
non-melanoma skin cancers (clinical use 2). It may also guide the surgery to provide more accurate presurgical margins (clinical use
3), preventing unnecessarily large scars and reducing the risk of recurrence.
Correlatively, DAMAE is developing a full software solution, based on a data storage cloud-platform, a computer-aided software
designed to assist dermatologists with OCTAV image interpretation, as well as telepathology and patient services.
OCTAV device will initially be used by clinicians as a routine easy-handling diagnostic device in public practices (market segment 1).
Implementation of OCTAV software will enable its adoption by a much larger market, consisting of private practices dermatologists
(market segment 2). The approach will contribute to the development of skin cancer risk patient awareness, while changing the
current paradigm through a timely, performant, and non-invasive approach, and releasing the financial burden on the healthcare
system.
Project OCTAV has successfully completed in 2017 a feasibility phase covered by the SME Instrument Phase 1, resulting in a TRL6
prototype of the technology and a first consolidated atlas of skin cancer clinical images. The main objective of this Phase2 is to
scaleup
the OCTAV solution to TRL9 through industrialization activities and by achieving a definitive market assessment, the clinical
validation and the regulatory approval, before deploying the approach worldwide.

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-2

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Coordinatore

DAMAE MEDICAL
Contribution nette de l'UE
€ 2 400 000,00
Indirizzo
Batiment 503 - campus scientifique d'orsay
91400 Orsay
Francia

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Ile-de-France Ile-de-France Essonne
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Altri finanziamenti
€ 1 085 857,00